TY - JOUR
T1 - The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in Vivo
AU - Helena Ng, Huei Leng
AU - Lyu, Aiping
AU - Lin, Ge
AU - Qin, Ling
AU - Yang, Zhijun
N1 - Publisher Copyright:
© 2014 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2014/12/24
Y1 - 2014/12/24
N2 - Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.
AB - Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.
KW - Anticancer ingredients
KW - Cancer cell penetrating peptides
KW - Carbonic anhydronase IX (CA-IX)
KW - Immunoliposomes
KW - In vivo delivery
UR - http://www.scopus.com/inward/record.url?scp=84919796690&partnerID=8YFLogxK
U2 - 10.3390/ijms16010230
DO - 10.3390/ijms16010230
M3 - Review article
C2 - 25547490
AN - SCOPUS:84919796690
SN - 1661-6596
VL - 16
SP - 230
EP - 255
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 1
ER -
